ALKERMES ($ALKS) posted quarterly earnings results for Q1 2026 on Tuesday, May 5th. The company reported earnings of -$0.40 per share, beating estimates of -$0.58 by $0.18. The company also reported revenue of $392,910,000, beating estimates of $367,044,960 by $25,865,040.
You can see Quiver Quantitative's $ALKS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALKERMES Insider Trading Activity
ALKERMES insiders have traded $ALKS stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by insiders over the last 6 months:
- SHANE COOKE has made 0 purchases and 2 sales selling 61,200 shares for an estimated $2,115,672.
- CRAIG C. HOPKINSON (EVP R&D, Chief Medical Officer) has made 0 purchases and 9 sales selling 52,748 shares for an estimated $1,684,685.
- DAVID JOSEPH GAFFIN (EVP, CLO, Alkermes, Inc.) has made 0 purchases and 4 sales selling 8,136 shares for an estimated $257,951.
- SAMUEL JOSEPH PARISI (VP, Finance (Interim PAO)) sold 6,890 shares for an estimated $201,808
- CHRISTIAN TODD NICHOLS (SVP, Chief Commercial Officer) sold 6,000 shares for an estimated $180,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
ALKERMES Hedge Fund Activity
We have seen 174 institutional investors add shares of ALKERMES stock to their portfolio, and 192 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 3,009,933 shares (-64.3%) from their portfolio in Q4 2025, for an estimated $84,217,925
- WELLINGTON MANAGEMENT GROUP LLP added 2,645,252 shares (+705.0%) to their portfolio in Q4 2025, for an estimated $74,014,150
- HOLOCENE ADVISORS, LP removed 2,469,030 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $69,083,459
- DEEP TRACK CAPITAL, LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $55,960,000
- BAKER BROS. ADVISORS LP added 1,920,916 shares (+23.7%) to their portfolio in Q4 2025, for an estimated $53,747,229
- UBS GROUP AG added 1,790,729 shares (+237.4%) to their portfolio in Q4 2025, for an estimated $50,104,597
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,719,334 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $48,106,965
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
ALKERMES Analyst Ratings
Wall Street analysts have issued reports on $ALKS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 11/17/2025
- Deutsche Bank issued a "Buy" rating on 11/13/2025
- Wells Fargo issued a "Overweight" rating on 11/13/2025
To track analyst ratings and price targets for ALKERMES, check out Quiver Quantitative's $ALKS forecast page.
ALKERMES Price Targets
Multiple analysts have issued price targets for $ALKS recently. We have seen 7 analysts offer price targets for $ALKS in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Jason Gerberry from B of A Securities set a target price of $36.0 on 04/09/2026
- David Amsellem from Piper Sandler set a target price of $43.0 on 03/24/2026
- Benjamin Burnett from Wells Fargo set a target price of $43.0 on 02/26/2026
- Leonid Timashev from RBC Capital set a target price of $45.0 on 02/26/2026
- Rudy Li from Wolfe Research set a target price of $45.0 on 02/24/2026
- Joon Lee from Truist Securities set a target price of $55.0 on 11/17/2025
- David Hoang from Deutsche Bank set a target price of $45.0 on 11/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
